

# **Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/C7950FC3E79AEN.html>

Date: August 2022

Pages: 27

Price: US\$ 3,500.00 (Single User License)

ID: C7950FC3E79AEN

## **Abstracts**

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Cathaeptsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Cathepsin B - Drugs In Development, 2022, outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds. It cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. The molecules developed by companies in Preclinical and Discovery stages are 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Infectious Disease and Oncology which include indications Alzheimer's Disease, Ebolavirus Infections (Ebola

Hemorrhagic Fever), Glioblastoma Multiforme (GBM), Schistosomiasis mansoni Infections and Traumatic Brain Injury.

Furthermore, this report also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)

The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Overview

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Companies

Involved in Therapeutics Development

ALSP Inc

Aviex Technologies LLC

Phelix Therapeutics LLC

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Drug Profiles

ALP-496 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AV-0213W - Drug Profile

Product Description

Mechanism Of Action

History of Events

CIBP-4 - Drug Profile

Product Description

Mechanism Of Action

Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Cathepsin B for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Dormant Products

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Product Development Milestones

Featured News & Press Releases

Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent

Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference  
January 25-27 in Santa Fe, New Mexico

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by ALSP Inc, 2022

Pipeline by Aviex Technologies LLC, 2022

Pipeline by Phelix Therapeutics LLC, 2022

Dormant Projects, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C7950FC3E79AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7950FC3E79AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970